Personalized Vaccines

 

1. Oncoquest™-L:

  • Description: Aggregon® with a recombinant human IL-2 and patient’s lymphoma cell lysate and / or patient specific neo-antigens in a synthetic multilamellar unit structure.

  • Stage: Phase II clinical trial ready

  • Clinical indication: Previously untreated Stage III or IV asymptomatic, non-bulky follicular lymphoma;

  • Proposed PI: Dr. Sattva Neelapu, M.D., Anderson Cancer Center, TX, IND # 15639

  • Status: Active, not recruiting patients

 

2. Oncoquest™-CLL:

  • Description: Aggregon® with a recombinant human IL-2 and patient’s leukemic cell lysate in a synthetic multilamellar unit structure.

  • Stage: Phase Ib clinical trial

  • Clinical indication: Treatment-naïve patients with Chronic lymphocytic leukemia;

  • PI: Dr. Shuo Ma, M.D., Northwestern University, Chicago; IND #: 15639

  • Status: Active, not recruiting patients

 

3. Oncoquest™-Ovarian cancer:

  • Description: Aggregon® with a recombinant human IL-2 and patient’s tumor cell lysate in a synthetic multilamellar unit structure.

  • Stage: Phase I / II clinical trial ready

  • Clinical indication: Patients with platinum-resistant, relapsed ovarian cancer.

  • PI: To be determined (Proposed location: Cancer Treatment Centers of America, GA)